Antimicrobial activity of 25 new original 2-aryliden-6-furfuryliden cyclohexanones and hexahydroindazoles based on them was studied. The majority of the compounds had low or moderate activity against the test cultures of Staphylococcus spp., Pseudomonas aeruginosa, Proteus spp. and Escherichia coil. Compound XIX (2,3-diphenyl-7-(5-nitrofurfuryliden)-3,3a,4,5,6,7-hexahydroindazole) with high antistaphylococcal activity was selected among several 2-aryliden-6-furfuryliden cyclohexanones and hexahydroindazoles. The activity of compound XIX was tested with the use of 105 clinical isolates of staphylococci. Comparative antistaphylococcal activity of compound XIX, furazolidone and sodium cefotaxime against the isolates was estimated. The impact of the microbial load, pH of the nutrient medium and the presence of 1%, 5% or 10% of serum or blood in the medium on the antimicrobial activity of compound XIX was evaluated. The results are in favour of further research on compound XIX as a potential agent of etiotropic therapy for staphylococcal infection.